Seagen Company Updates | Glassdoor.co.in

Company Updates

  • Breaking News: Seattle Genetics announces FDA filing acceptance for priority review of Tucatinib.

  • We’re proud to announce alongside our partner Astellas Pharma US, the U.S. FDA approval of the first antibody-drug conjugate for the treatment of adults with locally advanced or metastatic bladder cancer and other urothelial cancers. Thank you to the patients and families who participated the clinical trial leading to this approval, and to the doctors who led the research resulting in this new medicine for patients. http://glassdoor.com/slink.htm?key=vMghF

    FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

    First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 - - PADCEV is the First Treatment Approved for Locally Advanced or Metastatic Urothelial Cancer Following Treatment with Platinum-based Chemotherapy and a PD-1 or PD-L1 Inhibitor - Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc.

  • We are excited to announce positive topline results from a pivotal clinical trial evaluating our investigational agent in patients with metastatic HER2-positive breast cancer. Read more here: http://glassdoor.com/slink.htm?key=vMRle

    Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

    HER2CLIMB Trial Met Primary Endpoint and Both Key Secondary Endpoints- -Global Regulatory Strategy Includes NDA Submission to U.S. FDA Planned for First Quarter of 2020- -Data to be Presented at the 2019 San Antonio Breast Cancer Symposium- -Company to Host Conference Call Today at 9:00 a.m. EST- Seattle Genetics, Inc.

  • We are enthused to announce, alongside our partner Astellas, that the U.S. FDA accepted the Biologics License Application granting Priority Review for our investigational agent in advanced or metastatic urothelial cancer. We’re proud to advance bladder cancer research for patients. http://glassdoor.com/slink.htm?key=vMc3O

    Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer | Seattle Genetics Inc

    Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Sep. 16, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced

  • Thanks to our 2019 summer interns and good luck as you head back to class!

  • We are pleased to announce, along with our partner Astellas Pharma US, submission of a Biologics License Application (BLA) to the U.S. FDA for an investigational agent to treat advanced or metastatic #urothelial cancer #bladdercancer http://glassdoor.com/slink.htm?key=vMiak

    Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer | Seattle Genetics Inc

    Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 16, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ,

  • We're excited to announce the appointment of Robin Taylor, Ph.D., as Chief Commercial Officer http://glassdoor.com/slink.htm?key=vMEUX

    Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer | Seattle Genetics Inc

    BOTHELL, Wash. --(BUSINESS WIRE)--May 21, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G. Taylor , M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of

  • We presented positive phase 3 ALCANZA clinical trial data for cutaneous T-cell #lymphoma w/ @TakedaOncology at #ASH16 http://glassdoor.com/slink.htm?key=vQA9o

  • We’re excited to be at #ASH16 to discuss new research in #Hodgkin #lymphoma, as part of 18 abstracts & 8 oral presentations. http://glassdoor.com/slink.htm?key=vQA9Z

    Seattle Genetics, Inc.: Investors & News : Press Release

    ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

  • We’re wearing red for #BCAM. Let’s make the future brighter for everyone touched by lymphoma #LightItRed http://glassdoor.com/slink.htm?key=vI3M7

Work at Seagen? Share Your Experiences

Seagen
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or